Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) reported Q4 2025 revenue of $12.21B (up 7%) and full-year 2025 revenue of $44.56B (up 4%).
GAAP diluted EPS was $5.21 for Q4 and $17.74 for the year; adjusted EPS was $6.57 Q4 and $22.87 for 2025. The company deployed $16.5B of capital in 2025, including $13B for M&A and returned $3.6B to shareholders.
Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with NVIDIA on January 12, 2026 to integrate NVIDIA AI infrastructure into Thermo Fisher instruments and lab software.
The partnership will use NVIDIA DGX Spark, NVIDIA NeMo and NVIDIA BioNeMo to add AI-driven automation, improve accuracy and speed workflows, connect instruments and data to AI models, and advance autonomous or “lab-in-the-loop” scientific workflows that aim to reduce manual steps and accelerate research.
Henry Schein (Nasdaq: HSIC) appointed Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026. Mr. Lowery will join the Board of Directors and succeeds Stanley M. Bergman, who will step down as CEO after 35 years and remain Chairman to support a leadership transition. Mr. Lowery brings more than two decades of healthcare distribution and operations experience, most recently serving as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher (NYSE: TMO). The appointment is presented as alignment with Henry Schein’s BOLD+1 strategic plan and aims to accelerate growth and value creation.
Thermo Fisher Scientific (NYSE:TMO) announced that Marc N. Casper, chairman, president and CEO, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026 at 11:15 a.m. ET.
A live webcast will be available in the company's Investors section at www.thermofisher.com, with a replay accessible shortly after the presentation concludes.
Thermo Fisher Scientific (NYSE: TMO) will release its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, January 29, 2026. The company will hold a conference call the same day at 8:30 a.m. ET to discuss financial performance and future expectations.
The call will be webcast live in the Investors section of www.thermofisher.com. U.S. dial-in is (833) 470-1428; international dial-in is +1 (646) 844-6383; access code 054943. The earnings release and related materials will appear under Financials, and a replay will be available under News, Events & Presentations through Wednesday, April 22, 2026.
OlivePoint Capital and Redwood Capital acquired 3900 Paramount Parkway, a 220,000-square-foot Class A office building in Research Triangle Park, Raleigh–Durham, on December 15, 2025. The property is 100% leased to Pharmaceutical Product Development (PPD), a subsidiary of Thermo Fisher Scientific (NYSE: TMO), backed by long lease duration and corporate credit support.
The buyers said they purchased the asset at a discount to replacement cost and at an attractive in-place yield, citing office-sector dislocation as a sourcing opportunity and RTP’s strong tenant demand driven by life sciences and tech.
Thermo Fisher Scientific (NYSE:TMO) announced on December 2, 2025 an expansion of its Bioprocess Design Center network across Asia with a new center in Hyderabad, India and enlarged centers in Incheon, Korea and Singapore. The tri-hub network aims to provide localized expertise, bench-to-pilot capabilities, single-use and hybrid systems, and collaborative spaces to accelerate process development, training and scale-up for biologics, vaccines and cell and gene therapies.
The company said the expansion supports faster, more cost-effective and more sustainable biomanufacturing across Asia and was developed in partnership with the Government of Telangana for the Hyderabad site.
Thermo Fisher (NYSE: TMO) priced a €2.1 billion offering of euro-denominated senior notes, expected to close on or about December 1, 2025. The issuance comprises €1.0B floating-rate notes due 2027 and €1.1B fixed-rate notes due 2035 with a 3.628% coupon. The notes are fully guaranteed by Thermo Fisher and will pay interest quarterly (floating) or annually (fixed). Net proceeds are for general corporate purposes, including acquisitions, debt repayment, working capital, capex, or share repurchases.
Thermo Fisher Scientific (NYSE: TMO) announced 510(k) clearance in the U.S. on November 12, 2025 for the EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay, an automated diagnostic platform to aid in the diagnosis of multiple myeloma and related disorders.
The EXENT System claims enhanced sensitivity for detecting and isotyping M‑proteins, automated workflows with up to six hours of walkaway time per shift, no prior mass spectrometry experience required, and recent authorization for sale in Canada; availability is listed for multiple countries.
Thermo Fisher Scientific (NYSE:TMO) announced that its Board of Directors has authorized the repurchase of $5 billion of its common stock in the open market or in negotiated transactions.
The authorization has no expiration date, letting the company repurchase shares over time subject to market conditions and internal decisions.